Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations.

Anticancer Res. 1991 Mar-Apr;11(2):969-74. Unique Identifier : AIDSLINE MED/91290786
Brenner BG; Gryllis C; Gornitsky M; Cupples W; Wainberg M; Lady Davis Institute, Jewish General Hospital, Montreal, Quebec,; Canada.

Abstract: This study contrasts the effect of chemotherapy-induced and viral-induced (HIV-1) immunocompromise on natural killer (NK) and lymphokine-activated killer (LAK) cell function. The ability of NK and LAK cells isolated from the peripheral blood of healthy controls, breast cancer patients receiving or not receiving adjuvant chemotherapy, and HIV-1 seropositive individuals to lyse K562 and U937 targets was determined. Exponential regression analysis of the cytolytic data was used to derive the cytolytic variables A (indicative of the maximal cytolytic kill of a target) and k (indicative of the lytic efficiency of individual effector cells). Overall LU20 values were ascertained and adjusted to incorporate absolute lymphocyte numbers. Such analysis indicates that the cytolytic NK and progenitor LAK cell pools are diminished in breast cancer patients receiving chemotherapy. However, the ability of individual NK and LAK cells from treated patients to lyse targets remain unchanged. In contrast, the diminution of NK and LAK cell function in HIV-1 seropositive individuals is associated with reductions in both NK and LAK cell pool sizes as well as their cytolytic functions.

Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Analysis of Variance Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Breast Neoplasms/DRUG THERAPY/*IMMUNOLOGY Cells, Cultured Comparative Study Cytotoxicity, Immunologic Female Human *HIV Seropositivity HIV-1/*IMMUNOLOGY Killer Cells, Lymphokine-Activated/DRUG EFFECTS/*IMMUNOLOGY Killer Cells, Natural/DRUG EFFECTS/*IMMUNOLOGY Male Reference Values Regression Analysis Support, Non-U.S. Gov't Tamoxifen/ADVERSE EFFECTS/*THERAPEUTIC USE JOURNAL ARTICLE
911030
M91A0724

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .